surmount-1 trial tirzepatide weight loss results reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism The SURMOUNT-5 head-to-head results are

These effects were abolished by GLP-1R siRNA treatment, further demonstrating that GLP-1R may exert a protective effect in chondrocytes against ER-associated apoptosis in OA

The findings confirmed significant lean mass reductions in larger trials, though they noted that body composition improvements were generally favorable when looking at fat-to-lean ratios

While older medications target only one gut hormone, tirzepatide mimics two distinct, naturally occurring incretin hormones in the human body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)

one-way ANOVA, Tukeys multiple comparison post-hoc test, LFD group excluded